Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer - Full Text View

Purpose

RATIONALE: Adjuvant therapy given after surgery for early breast cancer may cause infertility. Assessing young women's attitudes and feelings about the risk of infertility may help improve the ability to plan effective treatment.

PURPOSE: This clinical trial is studying young women's attitudes and feelings about the risk of infertility related to adjuvant therapy for stage I or stage II breast cancer.

Condition	Intervention
Breast Cancer Cancer-Related Problem/Condition	Procedure: psychosocial assessment and care

Genetics Home Reference related topics:

breast cancer

MedlinePlus related topics:

Breast Cancer Cancer Infertility

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Other

Official Title:	A Survey of the Breast International Group (B.I.G.) to Assess the Attitude of Patients Aged Less Than 35 Years, With Early Breast Cancer, Toward the Risk of Loss of Fertility Related to Adjuvant Therapies

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Patients who would agree to have chemotherapy if it reduces their chances of having children as assessed by questionnaire [ Designated as safety issue: No ]

Estimated Enrollment:	385
Study Start Date:	May 2003
Estimated Primary Completion Date:	March 2008 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

Determine the attitude toward the risk of infertility related to adjuvant therapy in women with early breast cancer.
Correlate, if possible, the patient's attitude with the fact that the patient already has children or the time interval between the date of breast cancer diagnosis and the date of study participation.

OUTLINE: This is a multicenter study.

Patients complete a questionnaire administered by a nontreating physician.

PROJECTED ACCRUAL: A total of 385 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:	up to 35 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed prior or current diagnosis of breast cancer
- Stage I or II
- No relapsed disease
No evidence of infertility
- Regular menses or regular hormonal contraception use for the past 3 months
Hormonal status:
- Not specified

PATIENT CHARACTERISTICS:

Age

35 and under at diagnosis

Sex

Female

Menopausal status

Premenopausal

Performance status

Not specified

Life expectancy

Not specified

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Not specified

Other

No psychological, familial, sociological, or geographical condition that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

See Disease Characteristics

Radiotherapy

Not specified

Surgery

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00062400

Show 27 Study Locations

Sponsors and Collaborators

European Organization for Research and Treatment of Cancer

Investigators


Investigator:	Angelo Di Leo, MD	Misericordia e Dolce Hospital

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000304757, EORTC-10002, BIG-3-98
First Received:	June 5, 2003
Last Updated:	October 17, 2008
ClinicalTrials.gov Identifier:	NCT00062400
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

sexual dysfunction and infertility

sexuality and reproductive issues

psychosocial effects/treatment

stage I breast cancer

stage II breast cancer

Study placed in the following topic categories:

Infertility

Skin Diseases

Breast Neoplasms

Breast Diseases

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on November 30, 2008

Sponsored by:	European Organization for Research and Treatment of Cancer
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00062400